View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
August 28, 2012

Aeterna Zentaris begins Phase IIa trial in cancer cachexia patients

Aeterna Zentaris has recruited the first patient in a Phase IIa trial of AEZS-130, a ghrelin agonist, in cancer cachexia patients.

Aeterna Zentaris has recruited the first patient in a Phase IIa trial of AEZS-130, a ghrelin agonist, in cancer cachexia patients.

AEZS-130 is a novel orally-active small molecule that stimulates the secretion of growth hormones by binding to the ghrelin receptor (GHSR-1a).

The double-blind, randomised study, being conducted under a cooperative research and development agreement between Aeterna Zentaris and the Michael E DeBakey Veterans Affairs Medical Center, is designed to test the effects of different doses of AEZS-130 in 18 to 26 patients with cancer-cachexia.

Aeterna Zentaris president and CEO Juergen Engel said; "Because cachexia is very common among cancer patients, our oral ghrelin agonist, AEZS-130, could represent a novel treatment option for many of the 1.5m people diagnosed with cancer each year, in the US alone."

Following the safety and efficacy analysis at each dose level versus a placebo, which involves three sequential groups receiving differing doses of AEZS-130, the decision to either decrease or increase the dose will be taken.

Adequate efficacy is defined in the study as a =0.8kg of body weight gain or a =50ng/mL increase in plasma IGF-1 levels.

The safety and efficacy of repeated oral administration of AEZS-130 at different doses daily for one week, in view of developing a treatment for cachexia, is the primary objective of the placebo-controlled study.

Other secondary objectives include food intake and changes in appetite, muscle strength, energy expenditure, reward from food and functional brain connectivity.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU